HK Stock Market Move | GOLDENSOLAR (01121) rose more than 8%, the company collaborates with LONGi and Jinneng to jointly produce HBC products.
Jinyang New Energy (01121) rose more than 8%, rising to 8.25% as of the time of writing, reporting 2.1 Hong Kong dollars, with a turnover of 2.2779 million Hong Kong dollars.
GOLDENSOLAR (01121) rose more than 8%, as of the end of the publishing, it rose by 8.25%, to HKD 2.1, with a turnover of HKD 2.2779 million.
In terms of news, in September this year, GOLDENSOLAR announced that its indirect wholly-owned subsidiary, Jinyang (Quanzhou), had signed a joint venture agreement with Fujian Jnergy Electric Power Co., Ltd. and LONGi Green Energy Technology. The contracting parties have decided to establish a joint venture company to produce HBCCECEP Solar Energy cells, upgrading LONGi's four PERC production lines in Xi'an Aerospace Industry Base to efficient HBC production lines, and further packaging them into components for sale by LONGi or its affiliates. The company believes that through this cooperation, the group will be able to commercialize HBC product technology and replicate this cooperation model in the future to bring excellent returns to shareholders.
Prior to this, GOLDENSOLAR stated in its interim report that the group's goal is to establish a cluster of HBCCECEP Solar Energy cells and components based on the group's exclusive patents. Selectively cooperate with component manufacturers with high-end overseas channels to establish joint venture companies to exclusively produce HBCCECEP Solar Energy cells for them, manufacture them into components, and sell them overseas. Ultimately, the group aims to provide higher efficiency and more competitive HBC products for high-margin overseas markets, achieve technological differentiation, and differentiate from products with high homogeneity and facing severe price competition in the market.
Related Articles

New Stock News | Changguang Chenxin passes the hearing of Hong Kong Stock Exchange in 2024, ranking third in industrial imaging revenue among CIS companies worldwide

ANTON OILFIELD (03337) announced its performance for the year 2025, with a net profit attributable to shareholders of 373 million yuan, a year-on-year increase of 53.8%.

INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.
New Stock News | Changguang Chenxin passes the hearing of Hong Kong Stock Exchange in 2024, ranking third in industrial imaging revenue among CIS companies worldwide

ANTON OILFIELD (03337) announced its performance for the year 2025, with a net profit attributable to shareholders of 373 million yuan, a year-on-year increase of 53.8%.

INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


